Open Orphan PLC Appointment of Chair of Advisory Board (5329D)
20 February 2020 - 6:00PM
UK Regulatory
TIDMORPH
RNS Number : 5329D
Open Orphan PLC
20 February 2020
20 February 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Appointment of Professor Oxford as Chair of Advisory Board, with
initial focus to help guide Open Orphan in the provision of
solutions to Coronavirus outbreak
Open Orphan , the rapidly growing specialist CRO pharmaceutical
services company which has a focus on orphan drugs and is a world
leader in the provision of virology and vaccine challenge study
services, and has Europe's only 24 bedroom quarantine clinic with
onsite virology lab in Queen Mary's Hospital London, is pleased to
announce the appointment of Professor John Oxford as Chair of a
newly established Advisory Board. The Advisory Board will focus
initially on guiding Open Orphan in the provision of solutions to
the current Coronavirus outbreak.
The Advisory Board has been established to help the Company
support product development for customers developing antivirals,
vaccines and respiratory therapeutics, all particularly relevant
and topical in the environment of heightened awareness of the
Coronavirus in 2020.
Professor John Oxford, a Professor at Queen Mary's University
London and one of the world's leading experts on global diseases
such as influenza, including bird flu, SARS, MERS and Coronavirus,
will Chair the Advisory Board alongside Professor Brendan Buckley,
a Director of Open Orphan.
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman +44 (0)20 7347
Trevor Phillips, Chief Executive Officer 5350
Arden Partners plc (Nominated Adviser and
Joint Broker) +44 (0)20 7614
John Llewellyn-Lloyd / Benjamin Cryer 5900
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679
Anthony Farrell 6363
Camarco (Financial PR)
+44 (0)20 3757
Tom Huddart / Daniel Sherwen 4980
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.
Notes to Editors:
Open Orphan is a rapidly growing specialist CRO pharmaceutical
services company which has a focus on orphan drugs and is a world
leader in the provision of virology and vaccine challenge study
services and viral laboratory services. It has Europe's only
24-bedroom quarantine clinic with onsite virology lab in Queen
Mary's Hospital London. hVIVO supports product development for
customers developing antivirals, vaccines and respiratory
therapeutics, all particularly relevant and topical in the
environment of heightened awareness of the Coronavirus in 2020. The
company also has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. No other company in the world has such a
portfolio, with only two competitors globally having 1 challenge
study model each.
Open Orphan comprises of two commercial specialist CRO services
businesses (Venn and hVIVO) and is developing an early stage orphan
drug genomics data platform business. This platform captures
valuable genetic data from patient populations with specific
diseases with designated orphan drug status and incorporating AI
tools. In June 2019, Open Orphan acquired AIM-listed Venn Life
Sciences Holdings plc in a reverse take-over and in January 2020 it
completed the merger with hVIVO plc. Venn, as an integrated drug
development consultancy, offers CMC (c hemistry, manufacturing and
controls) , preclinical, phase I & II clinical trials design
and execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASFUEFUESSEDE
(END) Dow Jones Newswires
February 20, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024